Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study.


Journal

The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302

Informations de publication

Date de publication:
01 2022
Historique:
received: 07 04 2021
revised: 10 08 2021
accepted: 23 08 2021
pubmed: 20 11 2021
medline: 15 3 2022
entrez: 19 11 2021
Statut: ppublish

Résumé

Histopathological assessment of transplant biopsies is currently the standard method to diagnose allograft rejection and can help guide patient management, but it is one of the most challenging areas of pathology, requiring considerable expertise, time, and effort. We aimed to analyse the utility of deep learning to preclassify histology of kidney allograft biopsies into three main broad categories (ie, normal, rejection, and other diseases) as a potential biopsy triage system focusing on transplant rejection. We performed a retrospective, multicentre, proof-of-concept study using 5844 digital whole slide images of kidney allograft biopsies from 1948 patients. Kidney allograft biopsy samples were identified by a database search in the Departments of Pathology of the Amsterdam UMC, Amsterdam, Netherlands (1130 patients) and the University Medical Center Utrecht, Utrecht, Netherlands (717 patients). 101 consecutive kidney transplant biopsies were identified in the archive of the Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany. Convolutional neural networks (CNNs) were trained to classify allograft biopsies as normal, rejection, or other diseases. Three times cross-validation (1847 patients) and deployment on an external real-world cohort (101 patients) were used for validation. Area under the receiver operating characteristic curve (AUROC) was used as the main performance metric (the primary endpoint to assess CNN performance). Serial CNNs, first classifying kidney allograft biopsies as normal (AUROC 0·87 [ten times bootstrapped CI 0·85-0·88]) and disease (0·87 [0·86-0·88]), followed by a second CNN classifying biopsies classified as disease into rejection (0·75 [0·73-0·76]) and other diseases (0·75 [0·72-0·77]), showed similar AUROC in cross-validation and deployment on independent real-world data (first CNN normal AUROC 0·83 [0·80-0·85], disease 0·83 [0·73-0·91]; second CNN rejection 0·61 [0·51-0·70], other diseases 0·61 [0·50-0·74]). A single CNN classifying biopsies as normal, rejection, or other diseases showed similar performance in cross-validation (normal AUROC 0·80 [0·73-0·84], rejection 0·76 [0·66-0·80], other diseases 0·50 [0·36-0·57]) and generalised well for normal and rejection classes in the real-world data. Visualisation techniques highlighted rejection-relevant areas of biopsies in the tubulointerstitium. This study showed that deep learning-based classification of transplant biopsies could support pathological diagnostics of kidney allograft rejection. European Research Council; German Research Foundation; German Federal Ministries of Education and Research, Health, and Economic Affairs and Energy; Dutch Kidney Foundation; Human(e) AI Research Priority Area of the University of Amsterdam; and Max-Eder Programme of German Cancer Aid.

Sections du résumé

BACKGROUND
Histopathological assessment of transplant biopsies is currently the standard method to diagnose allograft rejection and can help guide patient management, but it is one of the most challenging areas of pathology, requiring considerable expertise, time, and effort. We aimed to analyse the utility of deep learning to preclassify histology of kidney allograft biopsies into three main broad categories (ie, normal, rejection, and other diseases) as a potential biopsy triage system focusing on transplant rejection.
METHODS
We performed a retrospective, multicentre, proof-of-concept study using 5844 digital whole slide images of kidney allograft biopsies from 1948 patients. Kidney allograft biopsy samples were identified by a database search in the Departments of Pathology of the Amsterdam UMC, Amsterdam, Netherlands (1130 patients) and the University Medical Center Utrecht, Utrecht, Netherlands (717 patients). 101 consecutive kidney transplant biopsies were identified in the archive of the Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany. Convolutional neural networks (CNNs) were trained to classify allograft biopsies as normal, rejection, or other diseases. Three times cross-validation (1847 patients) and deployment on an external real-world cohort (101 patients) were used for validation. Area under the receiver operating characteristic curve (AUROC) was used as the main performance metric (the primary endpoint to assess CNN performance).
FINDINGS
Serial CNNs, first classifying kidney allograft biopsies as normal (AUROC 0·87 [ten times bootstrapped CI 0·85-0·88]) and disease (0·87 [0·86-0·88]), followed by a second CNN classifying biopsies classified as disease into rejection (0·75 [0·73-0·76]) and other diseases (0·75 [0·72-0·77]), showed similar AUROC in cross-validation and deployment on independent real-world data (first CNN normal AUROC 0·83 [0·80-0·85], disease 0·83 [0·73-0·91]; second CNN rejection 0·61 [0·51-0·70], other diseases 0·61 [0·50-0·74]). A single CNN classifying biopsies as normal, rejection, or other diseases showed similar performance in cross-validation (normal AUROC 0·80 [0·73-0·84], rejection 0·76 [0·66-0·80], other diseases 0·50 [0·36-0·57]) and generalised well for normal and rejection classes in the real-world data. Visualisation techniques highlighted rejection-relevant areas of biopsies in the tubulointerstitium.
INTERPRETATION
This study showed that deep learning-based classification of transplant biopsies could support pathological diagnostics of kidney allograft rejection.
FUNDING
European Research Council; German Research Foundation; German Federal Ministries of Education and Research, Health, and Economic Affairs and Energy; Dutch Kidney Foundation; Human(e) AI Research Priority Area of the University of Amsterdam; and Max-Eder Programme of German Cancer Aid.

Identifiants

pubmed: 34794930
pii: S2589-7500(21)00211-9
doi: 10.1016/S2589-7500(21)00211-9
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e18-e26

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests JNK reports consulting roles for Owkin France and Panakeia (UK), outside of the submitted work; and honoraria for lectures from Merck Sharp & Dohme and Eisai and honoraria for participation in advisory board meetings of Merck Sharp & Dohme and Bayer, outside of the submitted work. All other authors declare no competing interests.

Auteurs

Jesper Kers (J)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Pathology, Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands; Van 't Hoff Institute for Molecular Sciences, University of Amsterdam, Amsterdam, Netherlands. Electronic address: j.kers@amsterdamumc.nl.

Roman D Bülow (RD)

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.

Barbara M Klinkhammer (BM)

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.

Gerben E Breimer (GE)

Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands.

Francesco Fontana (F)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Nephrology and Dialysis Unit, University Hospital of Modena, Modena, Italy.

Adeyemi Adefidipe Abiola (AA)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Morbid Anatomy and Forensic Medicine, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.

Rianne Hofstraat (R)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Van 't Hoff Institute for Molecular Sciences, University of Amsterdam, Amsterdam, Netherlands.

Garry L Corthals (GL)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Van 't Hoff Institute for Molecular Sciences, University of Amsterdam, Amsterdam, Netherlands.

Hessel Peters-Sengers (H)

Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Sonja Djudjaj (S)

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.

Saskia von Stillfried (S)

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.

David L Hölscher (DL)

Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.

Tobias T Pieters (TT)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands.

Arjan D van Zuilen (AD)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands.

Frederike J Bemelman (FJ)

Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Azam S Nurmohamed (AS)

Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Maarten Naesens (M)

Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium.

Joris J T H Roelofs (JJTH)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Sandrine Florquin (S)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Jürgen Floege (J)

Department of Nephrology and Immunology, RWTH Aachen University Hospital, Aachen, Germany.

Tri Q Nguyen (TQ)

Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands.

Jakob N Kather (JN)

Department of Medicine III, RWTH Aachen University Hospital, Aachen, Germany; Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

Peter Boor (P)

Department of Nephrology and Immunology, RWTH Aachen University Hospital, Aachen, Germany; Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany. Electronic address: pboor@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH